<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T09:53:23Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10713140" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10713140</identifier>
        <datestamp>2023-12-12</datestamp>
        <setSpec>jco</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">J Clin Oncol</journal-id>
              <journal-id journal-id-type="iso-abbrev">J Clin Oncol</journal-id>
              <journal-id journal-id-type="hwp">jco</journal-id>
              <journal-id journal-id-type="publisher-id">JCO</journal-id>
              <journal-title-group>
                <journal-title>Journal of Clinical Oncology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0732-183X</issn>
              <issn pub-type="epub">1527-7755</issn>
              <publisher>
                <publisher-name>Wolters Kluwer Health</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10713140</article-id>
              <article-id pub-id-type="pmcid">PMC10713140</article-id>
              <article-id pub-id-type="pmc-uid">10713140</article-id>
              <article-id pub-id-type="pmid">37695982</article-id>
              <article-id pub-id-type="pmid">37695982</article-id>
              <article-id pub-id-type="publisher-id">JCO.23.00296</article-id>
              <article-id pub-id-type="doi">10.1200/JCO.23.00296</article-id>
              <article-id pub-id-type="art-access-id">00005</article-id>
              <article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" article-version-type="Version of Record">3</article-version>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>CLINICAL TRIAL UPDATES</subject>
                  <subj-group>
                    <subject>Breast Cancer</subject>
                  </subj-group>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-2637-6906</contrib-id>
                  <name>
                    <surname>Goodwin</surname>
                    <given-names>Pamela J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="cor1" ref-type="corresp"/>
                  <xref rid="con1" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-6139-0696</contrib-id>
                  <name>
                    <surname>Chen</surname>
                    <given-names>Bingshu E.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4111-2757</contrib-id>
                  <name>
                    <surname>Gelmon</surname>
                    <given-names>Karen A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                  <xref rid="con2" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-9844-2023</contrib-id>
                  <name>
                    <surname>Whelan</surname>
                    <given-names>Timothy J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                  <xref rid="con3" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1094-5131</contrib-id>
                  <name>
                    <surname>Ennis</surname>
                    <given-names>Marguerite</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lemieux</surname>
                    <given-names>Julie</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                  <xref rid="con4" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0633-3151</contrib-id>
                  <name>
                    <surname>Ligibel</surname>
                    <given-names>Jennifer A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8807-153X</contrib-id>
                  <name>
                    <surname>Hershman</surname>
                    <given-names>Dawn L.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                  <xref rid="con5" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8147-335X</contrib-id>
                  <name>
                    <surname>Mayer</surname>
                    <given-names>Ingrid A.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                  <xref rid="con6" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-9877-3372</contrib-id>
                  <name>
                    <surname>Hobday</surname>
                    <given-names>Timothy J.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff10" ref-type="aff">
                    <sup>10</sup>
                  </xref>
                  <xref rid="con7" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7957-7424</contrib-id>
                  <name>
                    <surname>Bliss</surname>
                    <given-names>Judith M.</given-names>
                  </name>
                  <degrees>MSc</degrees>
                  <xref rid="aff11" ref-type="aff">
                    <sup>11</sup>
                  </xref>
                  <xref rid="con8" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6179-6407</contrib-id>
                  <name>
                    <surname>Rastogi</surname>
                    <given-names>Priya</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff12" ref-type="aff">
                    <sup>12</sup>
                  </xref>
                  <xref rid="con9" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rabaglio-Poretti</surname>
                    <given-names>Manuela</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff13" ref-type="aff">
                    <sup>13</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Thompson</surname>
                    <given-names>Alastair M.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff14" ref-type="aff">
                    <sup>14</sup>
                  </xref>
                  <xref rid="con10" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-7301-4030</contrib-id>
                  <name>
                    <surname>Rea</surname>
                    <given-names>Daniel W.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff15" ref-type="aff">
                    <sup>15</sup>
                  </xref>
                  <xref rid="con11" ref-type="fn"/>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stos</surname>
                    <given-names>Paul M.</given-names>
                  </name>
                  <degrees>BSc (Hon)</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-5035-1621</contrib-id>
                  <name>
                    <surname>Shepherd</surname>
                    <given-names>Lois E.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Stambolic</surname>
                    <given-names>Vuk</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="aff16" ref-type="aff">
                    <sup>16</sup>
                  </xref>
                  <xref rid="aff17" ref-type="aff">
                    <sup>17</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-6007-7494</contrib-id>
                  <name>
                    <surname>Parulekar</surname>
                    <given-names>Wendy R.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <aff id="aff1"><label><sup>1</sup></label>Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, and Department of Medicine, University of Toronto, Toronto, ON, <country>Canada</country></aff>
                <aff id="aff2"><label><sup>2</sup></label>Canadian Cancer Trials Group, Queen's University, Kingston, ON, <country>Canada</country></aff>
                <aff id="aff3"><label><sup>3</sup></label>University of British Columbia, BC Cancer Agency, Vancouver, BC, <country>Canada</country></aff>
                <aff id="aff4"><label><sup>4</sup></label>McMaster University, Juravinski Cancer Centre, Hamilton, ON, <country>Canada</country></aff>
                <aff id="aff5"><label><sup>5</sup></label>Applied Statistician, Markham, ON, <country>Canada</country></aff>
                <aff id="aff6"><label><sup>6</sup></label>CHU de Québec-Université Laval, Québec, QC, <country>Canada</country></aff>
                <aff id="aff7"><label><sup>7</sup></label>Dana-Farber Cancer Institute, Boston, MA</aff>
                <aff id="aff8"><label><sup>8</sup></label>Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY</aff>
                <aff id="aff9"><label><sup>9</sup></label>Vanderbilt University, Nashville, TN</aff>
                <aff id="aff10"><label><sup>10</sup></label>Mayo Clinic, Rochester, MN</aff>
                <aff id="aff11"><label><sup>11</sup></label>ICR-CTSU, Institute of Cancer Research (UK), London, United Kingdom</aff>
                <aff id="aff12"><label><sup>12</sup></label>NRG Oncology and University of Pittsburgh Medical Center, Pittsburgh, PA</aff>
                <aff id="aff13"><label><sup>13</sup></label>IBCSG and Department of Oncology, Bern University Hospital, University of Bern, Berne, Switzerland</aff>
                <aff id="aff14"><label><sup>14</sup></label>Baylor College of Medicine, Houston, TX</aff>
                <aff id="aff15"><label><sup>15</sup></label>Cancer Research UK Clinical Trials Unit (CRCTU), Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, <country>UK</country></aff>
                <aff id="aff16"><label><sup>16</sup></label>Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada</aff>
                <aff id="aff17"><label><sup>17</sup></label>Department of Medical Biophysics, University of Toronto, Toronto, ON, <country>Canada</country></aff>
              </contrib-group>
              <author-notes>
                <corresp id="cor1">Pamela J. Goodwin, MD, Mount Sinai Hospital, 1085-600 University Ave, Toronto, ON M5G 1X5, Canada; e-mail: <email>pamela.goodwin@sinaihealth.ca</email>.</corresp>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>10</day>
                <month>12</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="epub">
                <day>11</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>11</day>
                <month>9</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>41</volume>
              <issue>35</issue>
              <fpage>5356</fpage>
              <lpage>5362</lpage>
              <history>
                <date date-type="received">
                  <day>7</day>
                  <month>2</month>
                  <year>2023</year>
                </date>
                <date date-type="rev-recd">
                  <day>28</day>
                  <month>4</month>
                  <year>2023</year>
                </date>
                <date date-type="accepted">
                  <day>20</day>
                  <month>7</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>© 2023 by American Society of Clinical Oncology</copyright-statement>
                <copyright-year>2023</copyright-year>
                <copyright-holder>American Society of Clinical Oncology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>Creative Commons Attribution Non-Commercial No Derivatives 4.0 License: <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link></license-p>
                </license>
              </permissions>
              <self-uri xlink:href="jco-41-5356.pdf"/>
              <related-object source-id-type="registry-name" document-id="NCT01101438" document-id-type="clinical-trial-number" source-type="clinical-trials-registry" source-id="ClinicalTrials.gov" id="d64e372"/>
              <abstract>
                <p><italic toggle="yes">Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned coprimary or secondary analyses are not yet available. Clinical trial updates provide an opportunity to disseminate additional results from studies, published in</italic> JCO <italic toggle="yes">or elsewhere, for which the primary end point has already been reported.</italic></p>
                <p>Metformin has been associated with lower cancer risk in epidemiologic and preclinical research. In the MA.32 randomized adjuvant breast cancer trial, metformin (<italic toggle="yes">v</italic> placebo) did not affect invasive disease-free or overall survival. Here, we report metformin effects on the risk of new cancer. Between 2010 and 2013, 3,649 patients with breast cancer younger than 75 years without diabetes with high-risk T1-3, N0-3 M0 breast cancer (any estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2) were randomly assigned to metformin 850 mg orally twice a day or placebo twice a day for 5 years. New primary invasive cancers (outside the ipsilateral breast) developing as a first event were identified. Time to events was described by the competing risks method; two-sided likelihood ratio tests adjusting for age, BMI, smoking, and alcohol intake were used to compare metformin versus placebo arms. A total of 184 patients developed new invasive cancers: 102 metformin and 82 placebo, hazard ratio (HR), 1.25; 95% CI, 0.94 to 1.68; <italic toggle="yes">P</italic> = .13. These included 48 contralateral invasive breast cancers (27 metformin <italic toggle="yes">v</italic> 21 placebo), HR, 1.29; 95% CI, 0.72 to 2.27; <italic toggle="yes">P</italic> = .40 and 136 new nonbreast primary cancers (75 metformin <italic toggle="yes">v</italic> 61 placebo), HR, 1.24; 95% CI, 0.88 to 1.74; <italic toggle="yes">P</italic> = .21. Metformin did not reduce the risk of new cancer development in these nondiabetic patients with breast cancer.</p>
              </abstract>
              <abstract abstract-type="teaser">
                <p>Metformin (v placebo) did not prevent new cancers in nondiabetic patients with early breast cancer.</p>
              </abstract>
              <counts>
                <fig-count count="2"/>
                <table-count count="3"/>
                <equation-count count="0"/>
                <ref-count count="26"/>
                <page-count count="9"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <sec sec-type="introduction">
              <title>INTRODUCTION</title>
              <p>Metformin, a biguanide commonly used to treat type 2 diabetes, has been associated with lower overall cancer risk in epidemiologic studies conducted in patients with diabetes.<sup><xref rid="b1" ref-type="bibr">1</xref>,<xref rid="b2" ref-type="bibr">2</xref></sup> Meta-analyses of these studies have inconsistently identified lower risk of some types of cancer when individuals receive metformin.<sup><xref rid="b3" ref-type="bibr">3</xref>-<xref rid="b14" ref-type="bibr">14</xref></sup> It has been suggested that data from observational studies of metformin and cancer risk seem largely unreliable, studies using designs least likely to be affected by bias (notably selection and time-related biases) being most likely to yield results that did not support a causal effect of metformin on cancer risk.<sup><xref rid="b15" ref-type="bibr">15</xref>-<xref rid="b17" ref-type="bibr">17</xref></sup> The Diabetes Prevention Program trial, which randomly assigned adults with prediabetes to metformin, a lifestyle-based weight loss intervention or placebo, reported no effect of metformin versus placebo on cancer mortality at 21-year follow-up (hazard ratio [HR], 1.04; 95% CI, 0.72 to 1.52; <italic toggle="yes">P</italic> = .83).<sup><xref rid="b18" ref-type="bibr">18</xref></sup></p>
              <p>Current understanding of metformin action includes systemic effects resulting from reduced insulin signaling through PI3K/RAS pathways and cancer cell direct effects (notably LKB1–mediated activation of AMPK, a negative regulator of PI3K/Akt/mTOR signaling and protein synthesis). Some preclinical research suggests that metformin may lower cancer risk; however, translation to the clinical setting is not straightforward.<sup><xref rid="b19" ref-type="bibr">19</xref>,<xref rid="b20" ref-type="bibr">20</xref></sup></p>
              <p>Here, we report the effect of metformin versus placebo on new invasive cancers in MA.32, a phase III adjuvant randomized trial of metformin versus placebo in high-risk T1-3, N0-2, M0 breast cancer. We have previously reported the absence of an effect of metformin on invasive disease-free survival (IDFS) or overall survival in hormone receptor–positive or hormone receptor–negative breast cancer.<sup><xref rid="b21" ref-type="bibr">21</xref></sup> Exploratory analyses suggested beneficial effects in human epidermal growth factor receptor 2 (HER2)–positive breast cancer, notably in those with at least one C allele of the rs11212617 single-nucleotide polymorphism (SNP), a SNP associated with enhanced glycemic response and higher metformin blood levels in patients with diabetes.<sup><xref rid="b22" ref-type="bibr">22</xref>,<xref rid="b23" ref-type="bibr">23</xref></sup></p>
            </sec>
            <sec sec-type="methods">
              <title>METHODS</title>
              <p>Detailed methods have been reported previously.<sup><xref rid="b21" ref-type="bibr">21</xref></sup> Briefly, this investigator-initiated phase III randomized trial recruited patients (2010-2013) age 18-74 years, receiving standard therapy for a high-risk T1-3, N0-3, M0 breast cancer (excluding T1abN0) and diagnosed during the previous year. Exclusions included fasting glucose &gt;7.0 mmol/L, history of diabetes or lactic acidosis, current use of diabetes medication, previous recurrence or other invasive cancer, intake of ≥3 alcoholic drinks daily, or marked organ dysfunction. Random assignment (to metformin 850 mg orally twice a day or placebo orally twice a day for 5 years) was stratified for (1) estrogen receptor and/or progesterone receptor positive (≥1%) versus both negative (&lt;1%), (2) BMI ≤30 kg/m<sup>2</sup> versus &gt;30 kg/m<sup>2</sup>, (3) HER2 positive versus negative, and (4) any versus no adjuvant chemotherapy. In 2016, after a second interim analysis, futility was declared in hormone receptor–negative patients; study drug was discontinued in this group after a median exposure of 36.7 months, but blinded follow-up and event ascertainment continued.</p>
              <p>Our current focus was a secondary analysis of new primary invasive cancers in the contralateral breast (a protocol-specified secondary outcome) and exploratory analyses of new cancers elsewhere and overall (ipsilateral breast events were considered recurrences) that occurred as first IDFS events, with an exploration of whether effects of metformin differed by baseline BMI, insulin, glucose, homeostasis model assessment (HOMA, reflecting insulin resistance, calculated as glucose [mg/dL] × insulin [pmol/L]/22.5),<sup><xref rid="b24" ref-type="bibr">24</xref></sup> leptin and highly sensitive C-reactive protein (hsCRP) as well as smoking, rs11212617 SNP status, and receipt of adjuvant hormone therapy. Time to new cancer was analyzed by the competing risks method<sup><xref rid="b25" ref-type="bibr">25</xref></sup>; two-sided likelihood ratio tests adjusting for age, BMI, smoking (ever <italic toggle="yes">v</italic> never smoked), and alcohol (any <italic toggle="yes">v</italic> no intake during the past year), with other IDFS events as competing risk and censoring at the last follow-up without an IDFS event, were performed. MA.32 was approved by the Adult Central Institutional Review Board (National Institutes of Health) and institutional review boards of the participating institutions. Patients provided written informed consent to participate.</p>
            </sec>
            <sec sec-type="results">
              <title>RESULTS</title>
              <p>We randomly assigned 3,649 patients; all were included in intent-to-treat analyses. Baseline subject, tumor, and treatment characteristics were well balanced between study arms (Table <xref rid="tbl1" ref-type="table">1</xref>). The median follow-up and drug exposure were 95.9 (range, 0-121) months and 58.8 months, respectively.</p>
              <table-wrap position="float" id="tbl1">
                <label>TABLE 1.</label>
                <caption>
                  <p>Baseline Patient and Tumor Characteristics</p>
                </caption>
                <graphic xlink:href="jco-41-5356-g001" position="float"/>
              </table-wrap>
              <p>There were 184 new primary cancers reported as a first IDFS event, 102 on the metformin arm and 82 on the placebo arm (HR, 1.25; 95% CI, 0.94 to 1.68; <italic toggle="yes">P</italic> = .13; Fig <xref rid="fig1" ref-type="fig">1</xref>). Forty-eight were contralateral invasive breast cancers (27 metformin arm, 21 placebo arm), HR, 1.29 (95% CI, 0.72 to 2.27; <italic toggle="yes">P</italic> = .40), and 136 were nonbreast invasive cancers (75 metformin, 61 placebo), HR 1.24 (95% CI, 0.88 to 1.74; <italic toggle="yes">P</italic> = .21). The most common nonbreast cancers were gynecological (n = 31), lung (n = 26), hematological (n = 23), GI (n = 17), and melanoma (n = 13; Appendix Table A<xref rid="tblA1" ref-type="table">1</xref>, online only). The effect of metformin versus placebo on the risk of developing a new invasive cancer did not differ by hormone receptor status (positive HR, 1.19[ 95% CI, 0.83 to 1.69] <italic toggle="yes">v</italic> negative HR, 1.44 [95% CI, 0.86 to 2.41]) or HER2 status (positive HR, 0.83 [95% CI, 0.39 to 1.81] <italic toggle="yes">v</italic> negative HR, 1.36 [95% CI, 0.99 to 1.86]) of the primary tumor (interaction <italic toggle="yes">P</italic> values .53 and .25, respectively) or by receipt of adjuvant hormonal therapy (tamoxifen HR, 1.23 [95% CI, 0.73 to 2.08]; aromatase inhibitor HR, 1.34 [95% CI, 0.80 to 2.24]; none HR, 1.21 [95% CI, 0.75 to 1.95; interaction <italic toggle="yes">P</italic> value .96). Metformin effects were similar for obesity-associated cancers (invasive breast, colorectal, pancreatic, gastric cardia, ovary, uterus, kidney, thyroid, and myeloma)<sup><xref rid="b26" ref-type="bibr">26</xref></sup> and other cancers (HR, 1.18; 95% CI, 0.81-1.74; <italic toggle="yes">P</italic> = .39 and HR, 1.37; 95% CI, 0.88 to 2.13; <italic toggle="yes">P</italic> = .16, respectively) and for tobacco-associated (lung, head and neck, kidney, and bladder) and other cancers (HR, 1.77; 95% CI, 0.87 to 3.60; <italic toggle="yes">P</italic> = .11 and HR, 1.18; 95% CI, 0.85 to 1.62; <italic toggle="yes">P</italic> = .32). The effects of metformin did not differ by baseline levels of BMI (&lt;25, 25-30, &gt;30); quartiles of insulin, HOMA, leptin, and hsCRP; smoking (never, ever); and rs11212617 SNP status (any C <italic toggle="yes">v</italic> AA genotype; Table <xref rid="tbl2" ref-type="table">2</xref>). Ten patients developed contralateral ductal carcinoma in situ (eight metformin, two placebo); when these were included as cancers, the HR for metformin versus placebo for any breast cancer was 1.35 (95% CI, 0.77 to 2.37; <italic toggle="yes">P</italic> = .30) and for any cancer was 1.28 (95% CI, 0.95 to 1.70; <italic toggle="yes">P</italic> = .10).</p>
              <fig position="float" id="fig1" fig-type="figure">
                <label>FIG 1.</label>
                <caption>
                  <p>Cumulative incidence curves with respect to metformin and placebo for (A) any invasive cancer, (B) invasive breast cancer, (C) nonbreast invasive cancer, and (D) obesity-associated cance. <sup>a</sup>Obesity-associated cancers include invasive breast, colorectal, pancreatic, gastric cardia, ovary, uterus, kidney, thyroid, and myeloma. HR, hazard ratio.</p>
                </caption>
                <graphic xlink:href="jco-41-5356-g002" position="float"/>
              </fig>
              <table-wrap position="float" id="tbl2">
                <label>TABLE 2.</label>
                <caption>
                  <p>Effect of Metformin Versus Placebo on Cancer Risk in Relation to BMI, Metabolic Factors, Smoking, and rs11212617 SNP Status, With (unadjusted) HRs and Interaction <italic toggle="yes">P</italic> Values</p>
                </caption>
                <graphic xlink:href="jco-41-5356-g003" position="float"/>
              </table-wrap>
            </sec>
            <sec sec-type="discussion">
              <title>DISCUSSION</title>
              <p>The MA.32 trial provided a unique opportunity to examine the effects of metformin on the risk of developing new primary invasive cancers in a population without diabetes. Metformin did not affect the risk of new contralateral breast cancer, any invasive cancer, cancers outside of the breast, obesity, or tobacco-associated cancers. Point estimates of risk were all above 1, making it unlikely that additional power would have identified a clinically important reduction in risk. Furthermore, metformin did not reduce cancer risk in subgroups defined by BMI, metabolic factors (insulin, HOMA, leptin, hsCRP), smoking history, or rs11212617 SNP status, factors that could potentially be associated with metformin benefit.</p>
              <p>It is unclear whether our results are generalizable to populations with diabetes or prediabetes. Because of its beneficial physiologic effect, it is possible that metformin could reduce cancer risk in populations experiencing hyperglycemia, hyperinsulinemia, or inflammation. However, results of the Diabetes Prevention Program<sup><xref rid="b18" ref-type="bibr">18</xref></sup> and critical appraisals of the observational studies in populations with diabetes<sup><xref rid="b1" ref-type="bibr">1</xref>-<xref rid="b17" ref-type="bibr">17</xref></sup> discussed above raise concern about metformin benefit.</p>
              <p>These findings do not support the use of metformin to reduce risk of new primary cancers in patients without diabetes who have high-risk breast cancer.</p>
            </sec>
          </body>
          <back>
            <fn-group content-type="disclaimer">
              <title>DISCLAIMER</title>
              <fn specific-use="disclaimer" fn-type="other">
                <p>The study sponsors have no role in the design of the study; the collection, analysis, and interpretation of the data; the writing of the manuscript; and the decision to submit the manuscript for publication.</p>
              </fn>
            </fn-group>
            <fn-group content-type="supported-by">
              <title>SUPPORT</title>
              <fn specific-use="supported-by" fn-type="supported-by">
                <p>Supported by the Canadian Cancer Society Research Institute (No. 021039); National Cancer Institute (US; Nos. CA077202, CA180868, CA180822); The Breast Cancer Research Foundation (New York); Canadian Breast Cancer Foundation—Ontario Region, Ontario Institute for Cancer Research (No. 10NOV-467); Apotex Canada (in kind donation of placebo and metformin); and Hold'em for Life Charity.</p>
              </fn>
            </fn-group>
            <fn-group content-type="trial">
              <title>CLINICAL TRIAL INFORMATION</title>
              <fn specific-use="trial" fn-type="other">
                <p>
                  <ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT01101438" ext-link-type="uri">NCT01101438</ext-link>
                </p>
              </fn>
            </fn-group>
            <sec sec-type="data-availability">
              <title>DATA SHARING STATEMENT</title>
              <p>The primary efficacy analysis will be available from the Canadian Cancer trials Group (Kingston, ON). The associated data have been uploaded to the NCI data archive website: <ext-link xlink:href="http://http//nctn-data-archive.nci.nih.gov/view-trials" ext-link-type="uri">http//nctn-data-archive.nci.nih.gov/view-trials</ext-link> and will be searchable via ClinicalTrials.gov identifier (<ext-link xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT01101438" ext-link-type="uri">NCT1101438</ext-link>). Further information regarding that analysis and the data analyzed in this substudy can be obtained from the corresponding author.</p>
            </sec>
            <sec sec-type="contributed">
              <title>AUTHOR CONTRIBUTIONS</title>
              <p><bold>Conception and design:</bold> Pamela J. Goodwin, Bingshu E. Chen, Karen A. Gelmon, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Alastair M. Thompson, Vuk Stambolic, Wendy R. Parulekar</p>
              <p><bold>Provision of study materials or patients:</bold> Pamela J. Goodwin, Karen A. Gelmon, Julie Lemieux, Jennifer A. Ligibel, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Hobday, Priya Rastogi, Manuela Rabaglio-Poretti, Alastair M. Thompson, Daniel W. Rea, Wendy R. Parulekar</p>
              <p><bold>Collection and assembly of data:</bold> All authors</p>
              <p><bold>Data analysis and interpretation:</bold> Pamela J. Goodwin, Bingshu E. Chen, Karen A. Gelmon, Timothy J. Whelan, Marguerite Ennis, Julie Lemieux, Dawn L. Hershman, Ingrid A. Mayer, Timothy J. Hobday, Judith M. Bliss, Priya Rastogi, Alastair M. Thompson, Daniel W. Rea, Paul M. Stos, Vuk Stambolic, Wendy R. Parulekar</p>
              <p><bold>Manuscript writing:</bold> All authors</p>
              <p><bold>Final approval of manuscript:</bold> All authors</p>
              <p><bold>Accountable for all aspects of the work:</bold> All authors</p>
            </sec>
            <sec sec-type="COI-statement">
              <title>AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST</title>
              <sec>
                <title>Effect of Metformin Versus Placebo on New Primary Cancers in Canadian Cancer Trials Group MA.32: A Secondary Analysis of a Phase III Randomized Double-Blind Trial in Early Breast Cancer</title>
                <p>The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to <ext-link xlink:href="http://www.asco.org/rwc" ext-link-type="uri">www.asco.org/rwc</ext-link> or <ext-link xlink:href="https://ascopubs.org/jco/authors/author-center" ext-link-type="uri">ascopubs.org/jco/authors/author-center</ext-link>.</p>
                <p>Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (<ext-link xlink:href="https://openpaymentsdata.cms.gov/" ext-link-type="uri">Open Payments</ext-link>).</p>
                <fn-group content-type="COI-statement">
                  <fn id="con1" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Pamela J. Goodwin</bold>
                    </p>
                    <p><bold>Research Funding:</bold> Epic Sciences (Inst)</p>
                  </fn>
                  <fn id="con2" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Karen A. Gelmon</bold>
                    </p>
                    <p><bold>Honoraria:</bold> AstraZeneca, Merck Sharp &amp; Dohme, Seagen, Novartis Canada Pharmaceuticals Inc, Pfizer, Lilly, Gilead Sciences</p>
                    <p><bold>Consulting or Advisory Role:</bold> Pfizer, Novartis, Astrazeneca, Merck, Lilly, Roche, Mylan, Ayala Pharmaceuticals, Gilead Sciences</p>
                    <p><bold>Research Funding:</bold> Pfizer (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst)</p>
                    <p><bold>Expert Testimony:</bold> Genentech</p>
                  </fn>
                  <fn id="con3" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Timothy J. Whelan</bold>
                    </p>
                    <p><bold>Research Funding:</bold> Exact Sciences (Inst)</p>
                  </fn>
                  <fn id="con4" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Julie Lemieux</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> Novartis, Lilly, AstraZeneca, Gilead Sciences, Merck</p>
                    <p><bold>Research Funding:</bold> Imagia</p>
                    <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Patent related to health</p>
                  </fn>
                  <fn id="con5" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Dawn L. Hershman</bold>
                    </p>
                    <p><bold>Consulting or Advisory Role:</bold> AIM Specialty Health</p>
                  </fn>
                  <fn id="con6" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Ingrid A. Mayer</bold>
                    </p>
                    <p><bold>Employment:</bold> AstraZeneca</p>
                    <p><bold>Leadership:</bold> AstraZeneca</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> AstraZeneca</p>
                    <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Lilly, Genentech, Macrogenics, Pfizer, Seagen, Sanofi</p>
                    <p><bold>Research Funding:</bold> Novartis (Inst), Pfizer (Inst), Genentech (Inst)</p>
                  </fn>
                  <fn id="con7" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Timothy J. Hobday</bold>
                    </p>
                    <p><bold>Research Funding:</bold> Novartis (Inst)</p>
                  </fn>
                  <fn id="con8" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Judith M. Bliss</bold>
                    </p>
                    <p><bold>Research Funding:</bold> AstraZeneca (Inst), Merck Sharp &amp; Dohme (Inst), Puma Biotechnology (Inst), Pfizer (Inst), Roche (Inst), GlaxoSmithKline/Novartis (Inst), Lilly (Inst), Janssen-Cilag (Inst), Clovis Oncology (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer</p>
                  </fn>
                  <fn id="con9" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Priya Rastogi</bold>
                    </p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Genentech/Roche, Lilly, AstraZeneca</p>
                  </fn>
                  <fn id="con10" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Alastair M. Thompson</bold>
                    </p>
                    <p><bold>Employment:</bold> Lilly</p>
                    <p><bold>Stock and Other Ownership Interests:</bold> Lilly</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Endomagnetics</p>
                  </fn>
                  <fn id="con11" specific-use="COI-statement" fn-type="COI-statement">
                    <p>
                      <bold>Daniel W. Rea</bold>
                    </p>
                    <p><bold>Honoraria:</bold> Roche, Novartis, Pfizer, Lilly, AstraZeneca</p>
                    <p><bold>Research Funding:</bold> Celgene (Inst), Roche (Inst), bioTheranostics (Inst)</p>
                    <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, Daiichi Sankyo, eisai, Novartis</p>
                    <p>No other potential conflicts of interest were reported.</p>
                  </fn>
                </fn-group>
              </sec>
            </sec>
            <notes>
              <fn-group content-type="COI-statement">
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Pamela J. Goodwin</bold>
                  </p>
                  <p><bold>Research Funding:</bold> Epic Sciences (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Karen A. Gelmon</bold>
                  </p>
                  <p><bold>Honoraria:</bold> AstraZeneca, Merck Sharp &amp; Dohme, Seagen, Novartis Canada Pharmaceuticals Inc, Pfizer, Lilly, Gilead Sciences</p>
                  <p><bold>Consulting or Advisory Role:</bold> Pfizer, Novartis, Astrazeneca, Merck, Lilly, Roche, Mylan, Ayala Pharmaceuticals, Gilead Sciences</p>
                  <p><bold>Research Funding:</bold> Pfizer (Inst), Bristol Myers Squibb (Inst), AstraZeneca (Inst)</p>
                  <p><bold>Expert Testimony:</bold> Genentech</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Timothy J. Whelan</bold>
                  </p>
                  <p><bold>Research Funding:</bold> Exact Sciences (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Julie Lemieux</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> Novartis, Lilly, AstraZeneca, Gilead Sciences, Merck</p>
                  <p><bold>Research Funding:</bold> Imagia</p>
                  <p><bold>Patents, Royalties, Other Intellectual Property:</bold> Patent related to health</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Dawn L. Hershman</bold>
                  </p>
                  <p><bold>Consulting or Advisory Role:</bold> AIM Specialty Health</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Ingrid A. Mayer</bold>
                  </p>
                  <p><bold>Employment:</bold> AstraZeneca</p>
                  <p><bold>Leadership:</bold> AstraZeneca</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> AstraZeneca</p>
                  <p><bold>Consulting or Advisory Role:</bold> AstraZeneca, Lilly, Genentech, Macrogenics, Pfizer, Seagen, Sanofi</p>
                  <p><bold>Research Funding:</bold> Novartis (Inst), Pfizer (Inst), Genentech (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Timothy J. Hobday</bold>
                  </p>
                  <p><bold>Research Funding:</bold> Novartis (Inst)</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Judith M. Bliss</bold>
                  </p>
                  <p><bold>Research Funding:</bold> AstraZeneca (Inst), Merck Sharp &amp; Dohme (Inst), Puma Biotechnology (Inst), Pfizer (Inst), Roche (Inst), GlaxoSmithKline/Novartis (Inst), Lilly (Inst), Janssen-Cilag (Inst), Clovis Oncology (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Priya Rastogi</bold>
                  </p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Genentech/Roche, Lilly, AstraZeneca</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Alastair M. Thompson</bold>
                  </p>
                  <p><bold>Employment:</bold> Lilly</p>
                  <p><bold>Stock and Other Ownership Interests:</bold> Lilly</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Endomagnetics</p>
                </fn>
                <fn specific-use="COI-statement" fn-type="COI-statement">
                  <p>
                    <bold>Daniel W. Rea</bold>
                  </p>
                  <p><bold>Honoraria:</bold> Roche, Novartis, Pfizer, Lilly, AstraZeneca</p>
                  <p><bold>Research Funding:</bold> Celgene (Inst), Roche (Inst), bioTheranostics (Inst)</p>
                  <p><bold>Travel, Accommodations, Expenses:</bold> Pfizer, Daiichi Sankyo, eisai, Novartis</p>
                  <p>No other potential conflicts of interest were reported.</p>
                </fn>
              </fn-group>
            </notes>
            <app-group>
              <app id="app1">
                <title>APPENDIX</title>
                <table-wrap position="anchor" id="tblA1">
                  <label>TABLE A1.</label>
                  <caption>
                    <p>New Invasive Cancers Reported as a First Invasive Disease-Free Survival Event</p>
                  </caption>
                  <graphic xlink:href="jco-41-5356-g004" position="float"/>
                </table-wrap>
              </app>
            </app-group>
            <ref-list>
              <title>REFERENCES</title>
              <ref id="b1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>K</given-names></name><name><surname>Bai</surname><given-names>P</given-names></name><name><surname>Dai</surname><given-names>H</given-names></name><etal/></person-group>: <article-title>Metformin and risk of cancer among patients with type 2 diabetes mellitus: A systematic review and meta-analysis</article-title>. <source>Prim Care Diabetes</source><volume>15</volume>:<fpage>52</fpage>-<lpage>58</lpage>, <year>2021</year><pub-id pub-id-type="pmid">32605879</pub-id></mixed-citation>
              </ref>
              <ref id="b2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mekuria</surname><given-names>AN</given-names></name><name><surname>Ayele</surname><given-names>Y</given-names></name><name><surname>Tola</surname><given-names>A</given-names></name><etal/></person-group>: <article-title>Monotherapy with metformin versus sulfonylureas and risk of cancer in type 2 diabetic patients: A systematic review and meta-analysis</article-title>. <source>J Diabetes Res</source><volume>2019</volume>:<fpage>1</fpage>-<lpage>8</lpage>, <year>2019</year></mixed-citation>
              </ref>
              <ref id="b3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>GH</given-names></name><name><surname>Satkunam</surname><given-names>M</given-names></name><name><surname>Pond</surname><given-names>G</given-names></name><etal/></person-group>: <article-title>Association of metformin with breast cancer incidence and mortality in patients with type II diabetes: A GRADE-assessed systematic review and meta-analysis</article-title>. <source>Cancer Epidemiol Biomarkers Prev</source><volume>27</volume>:<fpage>627</fpage>-<lpage>635</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29618465</pub-id></mixed-citation>
              </ref>
              <ref id="b4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hevroni</surname><given-names>G</given-names></name><name><surname>Skwiersky</surname><given-names>S</given-names></name><name><surname>Zhyvotovska</surname><given-names>A</given-names></name><etal/></person-group>: <article-title>Metformin use and the risk of gastrointestinal malignancies in diabetic populations: A meta-analysis</article-title>. <source>Int J Clin Endocronol Metab</source><volume>6</volume>:<fpage>035</fpage>-<lpage>041</lpage>, <year>2020</year></mixed-citation>
              </ref>
              <ref id="b5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>C-AW</given-names></name><name><surname>Jiang</surname><given-names>AA</given-names></name><name><surname>Toh</surname><given-names>EMS</given-names></name><etal/></person-group>: <article-title>Metformin and colorectal cancer: A systematic review, meta-analysis and meta-regression</article-title>. <source>Int J Colorectal Dis</source><volume>35</volume>:<fpage>1501</fpage>-<lpage>1512</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32592092</pub-id></mixed-citation>
              </ref>
              <ref id="b6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yao</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>Y</given-names></name><etal/></person-group>: <article-title>Metformin use and lung cancer risk in diabetic patients: A systematic review and meta-analysis</article-title>. <source>Dis Markers</source><volume>2019</volume>:<fpage>6230162</fpage>, <year>2019</year><pub-id pub-id-type="pmid">30881522</pub-id></mixed-citation>
              </ref>
              <ref id="b7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group>: <article-title>Association of metformin use with ovarian cancer incidence and prognosis: A systematic review and meta-analysis</article-title>. <source>Int J Gynecol Cancer</source><volume>29</volume>:<fpage>140</fpage>-<lpage>146</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30640696</pub-id></mixed-citation>
              </ref>
              <ref id="b8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tian</surname><given-names>J</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Qu</surname><given-names>P</given-names></name></person-group>: <article-title>Antidiabetic medications and the risk of endometrial cancer in patients</article-title>. <source>Gynecol Obstet Invest</source><volume>84</volume>:<fpage>455</fpage>-<lpage>462</lpage>, <year>2019</year><pub-id pub-id-type="pmid">30808843</pub-id></mixed-citation>
              </ref>
              <ref id="b9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wen</surname><given-names>Q</given-names></name><name><surname>Zhao</surname><given-names>Z</given-names></name><name><surname>Wen</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>The association between metformin therapy and risk of gynecological cancer in patients: Two meta-analyses</article-title>. <source>Eur J Obstet Gynecol Reprod Biol</source><volume>237</volume>:<fpage>33</fpage>-<lpage>41</lpage>, <year>2019</year><pub-id pub-id-type="pmid">31009857</pub-id></mixed-citation>
              </ref>
              <ref id="b10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cui</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><etal/></person-group>: <article-title>Antidiabetic medications and the risk of prostate cancer in patients with diabetes mellitus: A systematic review and meta-analysis</article-title>. <source>Pharmacol Res</source><volume>177</volume>:<fpage>106094</fpage>, <year>2022</year><pub-id pub-id-type="pmid">35074527</pub-id></mixed-citation>
              </ref>
              <ref id="b11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feng</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>N</given-names></name><etal/></person-group>: <article-title>Metformin use and prostate cancer risk. A meta-analysis of cohort studies</article-title>. <source>Medicine</source><volume>98</volume>:<fpage>e14955</fpage>, <year>2019</year><pub-id pub-id-type="pmid">30896668</pub-id></mixed-citation>
              </ref>
              <ref id="b12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xiao</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>The effect of metformin on lung cancer risk and survival in patients with type 2 diabetes mellitus: A meta‐analysis</article-title>. <source>J Clin Pharm Ther</source><volume>45</volume>:<fpage>783</fpage>-<lpage>792</lpage>, <year>2020</year><pub-id pub-id-type="pmid">32406122</pub-id></mixed-citation>
              </ref>
              <ref id="b13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Cui</surname><given-names>Y</given-names></name><etal/></person-group>: <article-title>Association of metformin intake with bladder cancer risk and oncologic outcomes in type 2 diabetes mellitus patients. A systematic review and meta-analysis</article-title>. <source>Medicine</source><volume>97</volume>:<fpage>e11596</fpage>, <year>2018</year><pub-id pub-id-type="pmid">30045293</pub-id></mixed-citation>
              </ref>
              <ref id="b14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chang</surname><given-names>MS</given-names></name><name><surname>Hartman</surname><given-names>RI</given-names></name><name><surname>Xue</surname><given-names>J</given-names></name><etal/></person-group>: <article-title>Risk of skin cancer associated with metformin use: A meta-analysis of randomized controlled trials and observational studies</article-title>. <source>Cancer Prev Res</source><volume>14</volume>:<fpage>77</fpage>-<lpage>84</lpage>, <year>2021</year></mixed-citation>
              </ref>
              <ref id="b15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Suissa</surname><given-names>S</given-names></name><name><surname>Azoulay</surname><given-names>L</given-names></name></person-group>: <article-title>Metformin and the risk of cancer</article-title>. <source>Diabetes Care</source><volume>35</volume>:<fpage>2665</fpage>-<lpage>2673</lpage>, <year>2012</year><pub-id pub-id-type="pmid">23173135</pub-id></mixed-citation>
              </ref>
              <ref id="b16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Celotto</surname><given-names>S</given-names></name><name><surname>Pizzol</surname><given-names>D</given-names></name><etal/></person-group>: <article-title>Metformin and health outcomes: An umbrella review of systematic reviews with meta-analyses</article-title>. <source>Eur J Clin Invest</source><volume>51</volume>:<fpage>e13536</fpage>, <year>2021</year><pub-id pub-id-type="pmid">33709434</pub-id></mixed-citation>
              </ref>
              <ref id="b17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farmer</surname><given-names>RE</given-names></name><name><surname>Ford</surname><given-names>D</given-names></name><name><surname>Forbes</surname><given-names>HJ</given-names></name><etal/></person-group>: <article-title>Metformin and cancer in type 2 diabetes: A systematic review and comprehensive bias evaluation</article-title>. <source>Int J Epidemiol</source><volume>46</volume>:<fpage>745</fpage>-<lpage>744</lpage>, <year>2017</year><pub-id pub-id-type="pmid">28419306</pub-id></mixed-citation>
              </ref>
              <ref id="b18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>CG</given-names></name><name><surname>Hechman-Stoddard</surname><given-names>B</given-names></name><name><surname>Dabela</surname><given-names>D</given-names></name><etal/></person-group>: <article-title>Effect of metformin and lifestyle interventions on mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study</article-title>. <source>Diabetes Care</source><volume>44</volume>:<fpage>2775</fpage>-<lpage>2782</lpage>, <year>2021</year><pub-id pub-id-type="pmid">34697033</pub-id></mixed-citation>
              </ref>
              <ref id="b19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saini</surname><given-names>N</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group>: <article-title>Metformin as an anti-cancer agent: Actions and mechanisms targeting cancer stem cells</article-title>. <source>Acta Biochim Biophys Sin (Shanghai)</source><volume>50</volume>:<fpage>133</fpage>-<lpage>143</lpage>, <year>2018</year><pub-id pub-id-type="pmid">29342230</pub-id></mixed-citation>
              </ref>
              <ref id="b20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dowling</surname><given-names>RJ</given-names></name><name><surname>Niraula</surname><given-names>S</given-names></name><name><surname>Stambolic</surname><given-names>V</given-names></name><etal/></person-group>: <article-title>Metformin in cancer: Translational challenges</article-title>. <source>J Mol Endocrinol</source><volume>48</volume>:<fpage>R31</fpage>-<lpage>R43</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22355097</pub-id></mixed-citation>
              </ref>
              <ref id="b21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodwin</surname><given-names>PJ</given-names></name><name><surname>Chen</surname><given-names>BE</given-names></name><name><surname>Gelmon</surname><given-names>KA</given-names></name><etal/></person-group>: <article-title>Effect of metformin vs placebo on invasive disease-free survival in patients with breast cancer. The MA.32 randomized clinical trial</article-title>. <source>JAMA</source><volume>327</volume>:<fpage>1963</fpage>-<lpage>1973</lpage>, <year>2022</year><pub-id pub-id-type="pmid">35608580</pub-id></mixed-citation>
              </ref>
              <ref id="b22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Leeuwen</surname><given-names>N</given-names></name><name><surname>Nijpels</surname><given-names>G</given-names></name><name><surname>Becker</surname><given-names>ML</given-names></name><etal/></person-group>: <article-title>A gene variant near ATM is significantly associated with metformin treatment response in type 2 diabetes: A replication and meta-analysis of five cohorts</article-title>. <source>Diabetologia</source><volume>55</volume>:<fpage>1971</fpage>-<lpage>1977</lpage>, <year>2012</year><pub-id pub-id-type="pmid">22453232</pub-id></mixed-citation>
              </ref>
              <ref id="b23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luizon</surname><given-names>MR</given-names></name><name><surname>Eckalbar</surname><given-names>WL</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group>: <article-title>Genomic characterization of metformin hepatic response</article-title>. <source>PLoS Genet</source><volume>12</volume>:<fpage>e1006449</fpage>, <year>2016</year><pub-id pub-id-type="pmid">27902686</pub-id></mixed-citation>
              </ref>
              <ref id="b24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonora</surname><given-names>E</given-names></name><name><surname>Targher</surname><given-names>G</given-names></name><name><surname>Alberiche</surname><given-names>M</given-names></name><etal/></person-group>: <article-title>Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity</article-title>. <source>Diabetes Care</source><volume>23</volume>:<fpage>57</fpage>-<lpage>63</lpage>, <year>2000</year><pub-id pub-id-type="pmid">10857969</pub-id></mixed-citation>
              </ref>
              <ref id="b25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fine</surname><given-names>JP</given-names></name><name><surname>Gray</surname><given-names>RJ</given-names></name></person-group>: <article-title>A proportional hazards model for the subdistribution of a competing risk</article-title>. <source>J Am Stat Assoc</source><volume>94</volume>:<fpage>496</fpage>-<lpage>509</lpage>, <year>1999</year></mixed-citation>
              </ref>
              <ref id="b26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lauby-Secretan</surname><given-names>B</given-names></name><name><surname>Scoccianti</surname><given-names>C</given-names></name><name><surname>Loomis</surname><given-names>D</given-names></name><etal/></person-group>: <article-title>Body fatness and cancer—viewpoint of the IARC working group</article-title>. <source>N Engl J Med</source><volume>375</volume>:<fpage>794</fpage>-<lpage>798</lpage>, <year>2016</year><pub-id pub-id-type="pmid">27557308</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
